Osteosarcoma is a childhood cancer, usually affecting the bones of children and young adults during adolescent growth spurts. Most of the tumors are found in large bones such as the femur, tibia and humerus, though the tumors can occur in any bone. Although fewer than 1,000 new cases are diagnosed in the U.S. each year, the survival rate of children with osteosarcoma has remained at 60-65 percent since the 1980s.
IDM Pharma Inc. (Nasdaq: IDMI) concentrates on developing innovative cancer products that destroy cancer cells by activating immunity or preventing tumor recurrence. The company focuses on reaching full therapeutic and commercial potential for each of its products, including its resectable osteosarcoma treatment.
The company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) released a positive review of IDM’s L-MTP-PuE, or MEPACT, to treat resectable osteosarcoma. The committee also recommended that
...
Tags for this Post:cancer,
cancer products,
Committee for Medicinal Products for Human Use,
Europe,
european commission,
European Medicines Agency,
European Union,
Iceland,
IDM Pharma Inc.;,
Liechtenstein,
Norway,
Osteosarcoma;,
Small & Micro Cap,
Timothy P. Walbert;,
tumor,
tumors,
United States